Burnsed JC, et al. - Researchers conducted this retrospective study to report the institution's experience with gabapentin, a structural analogue of c-aminobutyric acid, therapy to manage agitation and pain in the neonatal intensive care unit (NICU) setting. Between January 2015 and December 2017, all neonates and infants admitted to the University of Virginia neonatal intensive care unit (NICU) who received gabapentin were included. For this analysis, data were obtained on neonatal agitation, pain, Neonatal Pain, Agitation and Sedation Scale scores, neurosedative medications, and adverse events. They started gabapentin in 16 individuals at a corrected gestational age of 44 weeks (range 36.2–75 weeks) for agitation (n = 9), pain (n = 6), and movement disorders (n = 1). In neonates and infants, gabapentin is well tolerated. Gabapentin is linked to reduced pain scores and lessened demand for multiple neurosedative medications 2 weeks following initiation.